About Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Gilead Sciences, Inc. (GILD) is a Healthcare company in the Drug Manufacturers - General industry with a market capitalisation of $179.6B. The stock yields 2.25%.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market cap
- $179.6B
- Forward P/E
- 14.64
- EPS (TTM)
- $-2.64
- Revenue (TTM)
- $30.5B
- Free cash flow
- $9.8B
- Profit margin
- -10.6%
- Dividend yield
- 2.25%
- Beta
- 0.35
- Shares outstanding
- 1.2B
Financial health: Fair6.8/10
7 strengths, 3 concerns. Weakest points: debt to equity, return on equity, net margin.
- Debt to equity: 1.10 (Concern, benchmark < 0.5) — Debt of 1.10x equity is high against the 0.5x benchmark. It has been broadly flat over the last 4 years.
- Net debt vs cash flow: 1.8y (Strong, benchmark < 4 years) — Net debt of $17.4B is 1.8x annual free cash flow — about 2 years of cash flow to repay.
- Current ratio: 1.55 (Strong, benchmark > 1.5) — Short-term assets cover 1.55x short-term liabilities, against Graham's 1.5x floor. It has improved over the last 4 years.
- Return on equity: -20.7% (Concern, benchmark > 15%) — Earns -20.7% on shareholder equity, well short of the > 15% mark.
- Gross margin: 79.6% (Strong, benchmark > 40%) — Keeps 79.6% of revenue after the direct cost of sales, comfortably past the > 40% mark.
- Net margin: -10.6% (Concern, benchmark > 10%) — Turns -10.6% of revenue into profit, well short of the > 10% mark.
- Free cash flow: $9.5B (Strong, benchmark positive) — Generated $9.5B of free cash flow after capital spending. It has improved over the last 4 years.
- Revenue growth: 10.2% (Strong, benchmark > 10%) — Revenue changed 10.2% year on year, comfortably past the > 10% mark.
- Earnings growth: 1672.9% (Strong, benchmark > 10%) — Earnings changed 1672.9% year on year, comfortably past the > 10% mark.
- PEG ratio: 1.95 (Watch, benchmark < 1) — At 1.95, the price looks fair relative to expected growth — Lynch treated 1.0 as fair value.
- Payout ratio: 43.4% (Strong, benchmark < 60%) — Pays out 43.4% of earnings as dividends, leaving room to keep paying.